Lineage Cell Therapeutics, Inc. (LCTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$36.5M
Cash & Equivalents
$8.1M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$319M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05919563 | LTFU Study of Subjects Who Received GRNOPC1 | OTHER | Active Not Recruiting | 5 |
| NCT05975424 | LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1 | OTHER | Active Not Recruiting | 25 |
| NCT06841770 | A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury | PHASE1 | Recruiting | 10 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.